

Gabriel Mircescu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6514040/publications.pdf>

Version: 2024-02-01

69
papers

1,606
citations

516215

16
h-index

344852

36
g-index

69
all docs

69
docs citations

69
times ranked

2092
citing authors

#	ARTICLE	IF	CITATIONS
1	MO833: Patient Benefits of Nephrological Follow-Up Before the Initiation of Rrtâ€”An Observational Retrospective Analysis. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
2	MO226: Is Remission of Hematuria Associated with Kidney Outcome in Biopsy-Proven Primary IGA Nephropathy?. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
3	MO586: Low-Protein Diet Supplemented With Ketoanalogues of Essential Amino Acids in Advanced Diabetic Kidney Disease: Safety Issues in Elderly. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
4	Non-diabetic glomerular lesions in diabetic kidney disease: clinical predictors and outcome in an Eastern European cohort. International Urology and Nephrology, 2021, 53, 739-747.	0.6	5
5	MO293NEUTROPHIL-TO-LYMPHOCYTE RATIO AND OUTCOME IN CRESCENTIC GLOMERULONEPHRITIS. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
6	Clinical Phenotypes and Predictors of Remission in Primary Membranous Nephropathy. Journal of Clinical Medicine, 2021, 10, 2624.	1.0	10
7	Low-salt low-protein diet and blood pressure control in patients with advanced diabetic kidney disease and heavy proteinuria. International Urology and Nephrology, 2021, 53, 1197-1207.	0.6	3
8	Long-Term Intravenous Iron Therapy and Morbidity in Hemodialysis Patients. MĂ dica, 2021, 16, 194-199.	0.4	0
9	Hydroxychloroquine in IgA nephropathy: a systematic review. Renal Failure, 2021, 43, 1520-1527.	0.8	13
10	Anti-phospholipase A2 receptor antibody screening in nephrotic syndrome may identify a distinct subset of patients with primary membranous nephropathy. International Urology and Nephrology, 2021, , 1.	0.6	4
11	Budd-Chiari syndrome: An unusual complication of an internal jugular tunneled dialysis catheter. Journal of Vascular Access, 2021, , 112972982110501.	0.5	0
12	Protein convertase subtilisin/kexin type 9 biology in nephrotic syndrome: implications for use as therapy. Nephrology Dialysis Transplantation, 2020, 35, 1663-1674.	0.4	13
13	Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney International, 2020, 98, 1540-1548.	2.6	380
14	Kidney Involvement in Hypocomplementemic Urticarial Vasculitis Syndromeâ€”A Case-Based Review. Journal of Clinical Medicine, 2020, 9, 2131.	1.0	21
15	P0113STANDARDIZED GRADING OF CHRONIC CHANGES IN MINIMAL CHANGE DISEASE: A VALIDATION STUDY IN NATIVE KIDNEY BIOPSY SPECIMENS. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
16	P0279DIABETIC KIDNEY DISEASE VERSUS CHRONIC KIDNEY DISEASE IN ADULTS WITHOUT DIABETES MELLITUS: A RENAL SURVIVAL ANALYSIS. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
17	P0426HISTOLOGICAL PREDICTORS OF RENAL PROGNOSIS IN LUPUS NEPHRITIS: WHICH COMPARTMENT MAKES THE DIFFERENCE?. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
18	â€œAssociatedâ€”or â€œSecondaryâ€”IgA nephropathy? An outcome analysis. PLoS ONE, 2019, 14, e0221014.	1.1	12

#	ARTICLE	IF	CITATIONS
19	Has The Time Arrived to Refine The Indications of Immunosuppressive Therapy and Prognosis in IgA Nephropathy?. Journal of Clinical Medicine, 2019, 8, 1584.	1.0	6
20	Consensus statement on the assessment of comorbidities in people living with HIV in Romania. Germs, 2019, 9, 198-210.	0.5	13
21	SP160IS AGE A DETERMINANT OF THE KIDNEY OUTCOME IN BIOPSY-PROVEN GLOMERULOPATHIES?. Nephrology Dialysis Transplantation, 2018, 33, i398-i398.	0.4	0
22	FP392FIBROBLAST GROWTH FACTOR 23 AND THE RISK OF RENAL REPLACEMENT THERAPY INITIATION IN NON-DIALYSIS CHRONIC KIDNEY DISEASE PATIENTS. Nephrology Dialysis Transplantation, 2018, 33, i166-i166.	0.4	0
23	FP073PROGNOSTIC SIGNIFICANCE OF RENAL BIOPSY IN ADULT ONSET MINIMAL CHANGE DISEASE. Nephrology Dialysis Transplantation, 2018, 33, i73-i73.	0.4	0
24	SP172SECONDARY VERSUS PRIMARY IGA NEPHROPATHY: ARE THERE ANY DIFFERENCES?. Nephrology Dialysis Transplantation, 2018, 33, i402-i402.	0.4	1
25	SP441DIABETES MELLITUS TYPE 2 AND CHRONIC KIDNEY DISEASE PROGRESSION IS THERE A DIFFERENCE?. Nephrology Dialysis Transplantation, 2018, 33, i496-i497.	0.4	0
26	Su0001HYPOPROTEIC DIET SUPPLEMENTED WITH KETOANALOGUES - EFFECTS ON PROTEINURIA IN PATIENTS WITH DIABETIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2018, 33, i617-i617.	0.4	2
27	FP393DOES ACTIVE OR NATIVE VITAMIN D SUPPLEMENTATION IMPROVE ARTERIAL STIFFNESS IN NON-DIALYSIS CHRONIC KIDNEY DISEASE PATIENTS?. Nephrology Dialysis Transplantation, 2018, 33, i166-i167.	0.4	0
28	Metabolic Acidosis of Chronic Kidney Disease and Cardiovascular Disorders. Mădica, 2018, 13, 267-272.	0.4	3
29	Metabolic acidosis of chronic kidney disease and subclinical cardiovascular disease markers. Medicine (United States), 2017, 96, e8802.	0.4	10
30	Perioperative Patient Blood Management Programme. Multidisciplinary recommendations from the Patient Blood Management Initiative Group. Romanian Journal of Anaesthesia and Intensive Care, 2017, 24, 139-157.	0.3	8
31	Subclinical cardiovascular disease markers and vitamin D deficiency in non-dialysis chronic kidney disease patients. Archives of Medical Science, 2016, 5, 1015-1022.	0.4	15
32	MP382DOES CHOLECALCIFEROL CORRECT SECONDARY HYPERPARATHYROIDISM IN NON-DIALYSIS CHRONIC KIDNEY DISEASE PATIENTS?. Nephrology Dialysis Transplantation, 2016, 31, i467-i467.	0.4	0
33	Validation study of Oxford Classification of IgA Nephropathy: the significance of extracapillary hypercellularity and mesangial IgG immunostaining. Pathology International, 2016, 66, 453-459.	0.6	18
34	Ketoanalogue-Supplemented Vegetarian Very Low-Protein Diet and CKD Progression. Journal of the American Society of Nephrology: JASN, 2016, 27, 2164-2176.	3.0	234
35	Hemodialysis system privatization and patient survival: a report from a large registry Eastern Europe cohort. Renal Failure, 2015, 37, 1481-1485.	0.8	6
36	Antiphospholipase A2 Receptor Autoantibodies: A Step Forward in the Management of Primary Membranous Nephropathy. BioMed Research International, 2015, 2015, 1-8.	0.9	22

#	ARTICLE	IF	CITATIONS
37	Bone marrow iron distribution, hepcidin, and ferroportin expression in renal anemia. <i>Hematology</i> , 2015, 20, 543-552.	0.7	16
38	New insights into the effect of haemodiafiltration on mortality: the Romanian experience. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 294-301.	0.4	32
39	ANCA positive crescentic glomerulonephritis outcome in a Central East European cohort: a retrospective study. <i>BMC Nephrology</i> , 2015, 16, 90.	0.8	22
40	Periodontal Status, Inflammation, and Malnutrition in Hemodialysis Patients – Is There a Link?. , 2015, 25, 67-74.		13
41	Pneumo-Renal Syndrome in Anti- Neutrophil Cytoplasm Antibody (ANCA)-Associated Small-Vessel Vasculitis. <i>MĂdica</i> , 2015, 10, 101-106.	0.4	0
42	Renal Transplantation in Romania: Where Do We Stand?. <i>MĂdica</i> , 2015, 10, 304-309.	0.4	2
43	Abdominal aortic calcification and renal resistive index in patients with chronic kidney disease: is there a connection?. <i>Journal of Nephrology</i> , 2014, 27, 173-179.	0.9	15
44	Outcomes of dialytic modalities in a large incident registry cohort from Eastern Europe: the Romanian Renal Registry. <i>International Urology and Nephrology</i> , 2014, 46, 443-451.	0.6	20
45	Risk factors for predicting venous thromboembolism in patients with nephrotic syndrome: focus on haemostasis-related parameters. <i>International Urology and Nephrology</i> , 2014, 46, 787-792.	0.6	17
46	Effects of additional iron doses on hepcidin-25 level in hemodialysis patients without evident iron deficiency. <i>International Urology and Nephrology</i> , 2014, 46, 1005-1012.	0.6	4
47	Catheter-related infections in chronic hemodialysis: a clinical and economic perspective. <i>International Urology and Nephrology</i> , 2013, 45, 817-823.	0.6	11
48	Effect of Low-Protein Diet Supplemented With Keto Acids on Progression of Chronic Kidney Disease. , 2013, 23, 210-213.		28
49	Does Dialysis Modality Influence the Oxidative Stress of Uremic Patients?. <i>Kidney and Blood Pressure Research</i> , 2012, 35, 220-225.	0.9	13
50	International Evaluation of Unrecognizably Uglifying Human Faces in Late and Severe Secondary Hyperparathyroidism in Chronic Kidney Disease. Sagliker Syndrome. A Unique Catastrophic Entity, Cytogenetic Studies for Chromosomal Abnormalities, Calcium-Sensing Receptor Gene and GNAS1 Mutations. Striking and Promising Missense Mutations on the GNAS1 Gene Exons 1, 4, 10, 4. , 2012, 22, 157-161.		23
51	Bone Marrow Iron, Iron Indices, and the Response to Intravenous Iron in Patients With Non-Dialysis-Dependent CKD. <i>American Journal of Kidney Diseases</i> , 2010, 55, 639-647.	2.1	82
52	Can the Response to Iron Therapy Be Predicted in Anemic Nondialysis Patients with Chronic Kidney Disease?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 409-416.	2.2	61
53	Surgical or medical therapy for severe hyperparathyroidism or chronic kidney disease? An appraisal of current practice guidelines. <i>Acta Endocrinologica</i> , 2010, 6, 541-576.	0.1	2
54	The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2722-2730.	0.4	63

#	ARTICLE	IF	CITATIONS
55	Nutritional Intervention in Uremia—Myth or Reality?. , 2010, 20, S31-S34.		7
56	Is Heparin-25 a Clinically Relevant Parameter for the Iron Status in Hemodialysis Patients?. , 2010, 20, S77-S83.		15
57	Oxidative Stress, Renal Anemia, and Its Therapies: Is There a Link?. , 2010, 20, S71-S76.		8
58	International Study on Sagliger Syndrome and Uglifying Human Face Appearance in Severe and Late Secondary Hyperparathyroidism in Chronic Kidney Disease Patients. , 2008, 18, 114-117.		19
59	Factors affecting the quality of life of haemodialysis patients from Romania: a multicentric study. Nephrology Dialysis Transplantation, 2008, 24, 626-629.	0.4	58
60	Oxidative Stress of Chronic Kidney Disease. Acta Endocrinologica, 2008, 4, 433-446.	0.1	6
61	Effects of a Supplemented Hypoproteic Diet in Chronic Kidney Disease. , 2007, 17, 179-188.		85
62	Oxidative Stress: An Accomplice to Uremic Toxicity?. , 2006, 16, 194-198.		22
63	The Success Story of Peritoneal Dialysis in Romania: Analysis of Differences in Mortality by Dialysis Modality and Influence of Risk Factors in a National Cohort. Peritoneal Dialysis International, 2006, 26, 266-275.	1.1	18
64	Once-Every-2-Weeks and Once-Weekly Epoetin Beta Regimens: Equivalency in Hemodialyzed Patients. American Journal of Kidney Diseases, 2006, 48, 445-455.	2.1	6
65	Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients. Nephrology Dialysis Transplantation, 2006, 21, 120-124.	0.4	91
66	The success story of peritoneal dialysis in Romania: analysis of differences in mortality by dialysis modality and influence of risk factors in a national cohort. Peritoneal Dialysis International, 2006, 26, 266-75.	1.1	10
67	Influence of Epoietin Therapy on the Oxidative Stress in Haemodialysis Patients. Nephron Clinical Practice, 2005, 100, c126-c132.	2.3	7
68	Global assessment of serum antioxidant status in hemodialysis patients. Journal of Nephrology, 2005, 18, 599-605.	0.9	11
69	Nephrology and renal replacement therapy in Romania—transition still continues (Cinderella story) Tj ETQq1 1 0.784314 rgBT ₂₀ Overlo	0.4	20